Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- PMID: 32184169
- DOI: 10.1016/j.gene.2020.144549
Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease and associated with a wide spectrum of hepatic disorders ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). NASH is projected to become the most common indication for liver transplantation, and the annual incidence rate of NASH-related HCC is 5.29 cases per 1000 person-years. Owing to the epidemics of NAFLD and the unclear mechanism of NAFLD progression, it is important to elucidate the underlying NAFLD mechanisms in detail. NASH is mainly caused by the development of NAFL Therefore, it is also of great significance to understand the mechanism of progression from NAFL to NASH. Gene expression chip data for NAFLD and NASH were downloaded from the Gene Expression Omnibus database to identify differentially expressed genes (DEGs) between NAFLD and normal controls (called DEGs for NAFLD), as well as between NASH and normal tissue (called DEGs for NASH-Normal), and between NASH and NAFL tissue (called DEGs for NASH-NAFL). For DEGs for the NAFLD group, key genes were identified by studying the form of intersection. Potential functions of DEGs for NASH were then analyzed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. A protein-protein interaction network (PPI) was constructed using the STRING database. A total of 249 DEGs and one key gene for NAFLD were identified. For NASH-Normal, 514 DEGs and 11 hub genes were identified, three of which were closely related to the survival analysis of HCC, and potentially closely related to progression from NASH to HCC. One key gene for NASH-NAFL (AKR1B10) was identified. These genes appear to mediate the molecular mechanism underlying NAFLD and may be promising biomarkers for the presence of NASH.
Keywords: Differentially expressed genes (DEGs); Microarray; Non-alcoholic steatohepatitis (NASH); Nonalcoholic fatty liver disease (NAFLD); Protein–protein interaction (PPI).
Copyright © 2020. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis.Front Endocrinol (Lausanne). 2020 Nov 26;11:601745. doi: 10.3389/fendo.2020.601745. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33324350 Free PMC article.
-
Microarray-based Detection of Critical Overexpressed Genes in the Progression of Hepatic Fibrosis in Non-alcoholic Fatty Liver Disease: A Protein-protein Interaction Network Analysis.Curr Med Chem. 2024;31(23):3631-3652. doi: 10.2174/0929867330666230516123028. Curr Med Chem. 2024. PMID: 37194229
-
Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study.Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):433-451. doi: 10.1016/j.hbpd.2021.06.001. Epub 2021 Jun 25. Hepatobiliary Pancreat Dis Int. 2021. PMID: 34233850
-
Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.Curr Vasc Pharmacol. 2018;16(3):214-218. doi: 10.2174/1570161115666170621075157. Curr Vasc Pharmacol. 2018. PMID: 28676025 Review.
-
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. World J Gastroenterol. 2014. PMID: 25400438 Free PMC article. Review.
Cited by
-
Update cognition of nonalcoholic fatty liver disease/metabolism-associated fatty liver disease.Chronic Dis Transl Med. 2022 Mar 2;8(1):5-6. doi: 10.1002/cdt3.14. eCollection 2022 Mar. Chronic Dis Transl Med. 2022. PMID: 35620163 Free PMC article. No abstract available.
-
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):46-56. doi: 10.1038/s41575-023-00846-4. Epub 2023 Oct 5. Nat Rev Gastroenterol Hepatol. 2024. PMID: 37798441 Review.
-
Exploring the possible therapeutic mechanism of Danzhixiaoyao pills in depression and MAFLD based on "Homotherapy for heteropathy": A network pharmacology and molecular docking.Heliyon. 2024 Jul 26;10(15):e35309. doi: 10.1016/j.heliyon.2024.e35309. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170292 Free PMC article.
-
Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis.Int J Mol Sci. 2022 May 1;23(9):5035. doi: 10.3390/ijms23095035. Int J Mol Sci. 2022. PMID: 35563425 Free PMC article.
-
Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis.Front Endocrinol (Lausanne). 2020 Nov 26;11:601745. doi: 10.3389/fendo.2020.601745. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33324350 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical